Couchbase Announces Closing of Initial Public Offering prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BERKELEY, Calif. (BUSINESS WIRE) Jul 22, 2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Caribou. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Caribou, are expected to be $304.0 million. In addition, Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
Form S-1/A Caribou Biosciences, streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share:
FREMONT, Calif., July 22, 2021 (GLOBE NEWSWIRE) Cytek Biosciences, Inc. ( Cytek Biosciences or Cytek ) (NASDAQ:CTKB), a leading cell analysis solutions company, announced today the pricing of its initial public offering of an aggregate of 16,749,330 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Cytek from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $200 million. Cytek is offering 11,764,706 shares of common stock and the selling stockholders named in the prospectus are offering 2,799,929 shares of common stock. Cytek will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Cytek has granted the underwriters a 30-day option to purchase up to an additional 2,184,695 shares of common stock solely to cover over-allotments, if any, at the initial public offering price, less underwriting discounts and commissions
Cytek Biosciences Announces Pricing of Its Initial Public Offering
July 22, 2021 22:43 ET | Source: Cytek Biosciences, Inc. Cytek Biosciences, Inc. Fremont, California, UNITED STATES
FREMONT, Calif., July 22, 2021 (GLOBE NEWSWIRE) Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the pricing of its initial public offering of an aggregate of 16,749,330 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Cytek from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $200 million. Cytek is offering 11,764,706 shares of common stock and the selling stockholders named in the prospectus are offering 2,799,929 shares of common stock. Cytek will not receive any proceeds from the sale of shares by the selling stockholders. In addition,